Departments and Services | For Patients | Research & Trials | Education | Find a Doctor


Search:
Division of Infectious Disease
 
    
Division of Infections Disease
 
Home
Fellowship Program
Clinical Programs
Penn CDC Prevention Epicenters Program
Clinical Trials
Penn CFAR
Botswana-UPenn Partnership
Seminars
Faculty
Adjunct Faculty
Administrative Contacts
Outpatient Clinics
News

Faculty

faculty photo

Karam C. Mounzer, MD

Clinical Associate Professor of Medicine
Attending Physician, Penn Presbyterian Medical Center
Department: Medicine

Contact information
1233 Locust Street
Philadelphia, PA 19107
Office: 2157901788
Fax: 2157325490
Education:
Bachelor (Experimental Sciences and French Literature)
Notre Dame Jamhour- Jesuite School 1982-1985, 1985.
MD
Saint Joseph University (Pre-Med & Med combined) Faculty of Medicine, Lebanon 1985-1992, 1992.
Post-Graduate Training
Internal Medicine, Cooper Health System - University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Camden , 1992-1993.
Residency, Cooper Health System - University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Camden , 1993-1995.
Infectious Diseases Fellowship, Cooper Health System - University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Camden , 1995-1997.
Certifications
Diplomate, American Board of Internal Medicine , 1995.
Diplomate, American Board of Infectious Diseases , 1997.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Clinical Development of new antiretroviral agents

Description of Clinical Expertise

Treatment of Multi drug Resistant HIV virus, HIV-HCV co-infection

Description of Other Expertise

Suboxone Clinic for HIV infected opioid-addicted patients

Selected Publications

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, Baker D, Moore R, Read T, Roth N, Clumeck N, Florence E, Moutschen M, Vandekerckhove L, Boissonnault M, Conway B, De Wet J, Gill J, Kasper K, Rosengren O, Smith G, Tsoukas C, Walmsley S, Gerstoft J, Ajana F, Durant J, Hocqueloux L, Khuong-Josses MA, Partisani M, Pialoux G, Yazdanpanah Y, Arasteh K, Baumgarten A, Eberhard A, Esser S, Jaeger H, Kuhlmann B, Ole Jensen BE, Lutz T, Stellbrink HJ, Stephan C, Trein A, Antinori A, Bassi P, Di Biagio A, Lazzarin A, Maggiolo F, Mazzotta F, van der Ende ME, Duiculescu D, Rugina S, Streinu-Cercel A, Antela A, Arribas JR, Barros C, Berenguer J, Cano Sánchez A, Clotet Sala B, Deig Comerma E, Domingo P, Estrada V, Flores Cid J, Galindo MJ, Gomez Sirvent JL, Goenaga MA, Gutierrez Rodero F, Hernández-Mora MG, Ibarra Ugarte S, Marquez M, Moreno Guillen S, Ocampo Hermida A, Lopez Aldeguer J, Oteo Revuelta JA, Pasquau J, Portilla J, Podzamczer Palter D, Peñaranda Vera M, Ribera E, Rubio R, Sanz J, Sanz Moreno J, Soriano V, Telenti M, Torres Perea R, Viciana Fernández P, Fox J, Hay P, Johnson M, Kegg S, Nwokolo N, Taylor S, Teague A, Bredeek U, Cade J, DeJesus E, Edelstein H, Elion R, Eron J Jr, Evans C, Feinberg J, Felizarta F, Goulston C, Hanna B, Henry WK, Hicks C, Huhn G, Hsu R, Jefferson T, Johnson M, Johnson P, Kilby J, Kumar P, Lalezari J, Markowitz M, Martorell C, McDonald C, Meier J, Mills A, Mounzer K, Murphy M, Newman C, Nguyen T, O'Keefe P,: Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. The New England journal of medicine 369(19): 1807-18, Nov 2013.

Mounzer KC, DiNubile MJ: Seminal human immunodeficiency virus blips and structured natural conception in serodiscordant couples. The Journal of infectious diseases 208(4): 710-1, Aug 2013.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, O'Doherty U, Kostman J, Montaner LJ: Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van Lunzen. The Journal of infectious diseases 208(2): 363, Jul 2013.

Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F, Kumar P, Thompson M, Campo RE, Mounzer K, Strohmaier KM, Lu C, Rodgers A, Jackson BE, Wenning LA, Robertson M, Nguyen BYT, Sklar P: Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. AIDS research and human retroviruses 29(6): 859-70, Jun 2013.

Momplaisir F, Mounzer K, Long JA: Preventive cancer screening practices in HIV-positive patients. AIDS care Jun 2013.

Koenig HC, Garland JM, Weissman D, Mounzer K: Vaccinating HIV patients: focus on human papillomavirus and herpes zoster vaccines. AIDS reviews 15(2): 77-86, Apr-Jun 2013.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O'Doherty U, Kostman J, Montaner LJ: Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. The Journal of infectious diseases 207(2): 213-22, Jan 2013.

Gekonge B, Raymond AD, Yin X, Kostman J, Mounzer K, Collman RG, Showe L, Montaner LJ: Retinoblastoma protein induction by HIV viremia or CCR5 in monocytes exposed to HIV-1 mediates protection from activation-induced apoptosis: ex vivo and in vitro study. Journal of leukocyte biology 92(2): 397-405, Aug 2012.

Nelson M, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P, Li T, Tebas P, Stevens M, Buelens A, Vanveggel S, Boven K: Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. The Journal of antimicrobial chemotherapy 67(8): 2020-8, Aug 2012.

DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379(9835): 2429-38, Jun 2012.

back to top
Last updated: 03/20/2014
The Trustees of the University of Pennsylvania